Good morning, everyone. Thank you. Michael Yee, Global Head of Biotechnology here at UBS, Senior Biotechnology Analyst. Very excited to have members of the team of Vertex Pharmaceuticals up here with us. Members of the IR team, Susie Lisa and Manisha Pai. Thank you guys for being here.
Thanks for having us.
Absolutely. Exciting times, never a dull moment for Vertex. We had an investor dinner last night. Vertex, of course, one of the most important talking points because you have so much going on, including PDUFA dates and all sorts of exciting things. Maybe the first opening question would be just tell us about the business as it stands today with the focus on the execution of CF and, of course, some of the pipeline. So maybe just give us an introduction to the most important milestones coming up for Vertex. I think most people know Vertex, but how you guys are feeling about the business right now and some of the most important milestones.
Sure. I'll try and do a quick tour.
Quick tour.
Coming off very strong third quarter results, which we're pleased to see really nice balanced growth from CF in the U.S. and internationally, and good progress from our ongoing launches in products outside of CF, namely JOURNAVX and CASGEVY, which remain on track to contribute north of $500 million this year to our total $13 billion plus guidance in revenue for the year. I think that during the quarter, you had some pretty good clinical milestones, including the AMPLIFIED results for inaxaplin in additional patient populations, and that's one of the key catalysts coming up. I'll go in sequential order to make things easy, if you will. The next key catalyst will be the November 30th PDUFA date for povetacicept in immunoglobulin A nephropathy. We are launch-ready. We've had our launch-ready meeting.
We're very excited, have had very good interactions with FDA, things remain on track, and are ready to go November 30th. That'll be the first launch in our new renal franchise, which is an exciting time for us given that we now have not only the CF franchise, but commercialized in sickle cell disease with CASGEVY, in acute pain with JOURNAVX, now in acromegaly with PALSONIFY post the Crinetics acquisition, which also had a good September result. Then we'll be excited to enter into our fifth area with IgAN as the first of four pipeline products in renal. November 30th is the PDUFA date. We also have promised before the end of the year results in myotonic dystrophy type 1. That'll be a phase II proof of concept study.
Obviously, a tough disease, lots happening out there, but happy to talk about that in more detail if you'd like. We said in the first quarter of 2027, you will get the interim analysis from the phase III study called AMPLITUDE for inaxaplin in APOL1-mediated kidney disease. We're really looking forward to that. If positive, that would put us on the path for accelerated approval in the U.S. In the first half of the year, you'll also get the results from the two phase III studies that are ongoing in diabetic peripheral neuropathy.
This would be the potential for the first indication in chronic pain to complement what we're doing in acute pain for JOURNAVX. I think those are some of the big key catalysts coming up, and I'm happy to jump into your specific-
So much that I can't get through it in the next 25 minutes. All right. We'll try and stay focused. In the near term, as you mentioned, November 30th PDUFA date. On the [earnings] call just a couple weeks ago, Vertex remains confident in the approval. I'm not exactly sure why there's even a debate, but maybe you could just speak to your confidence because on one side, people worry that the contract manufacturer specifically is a new contract manufacturer that is supporting the manufacturing of pove. On the other hand, the data results are obviously very strong. There's been multiple other recent approvals, so it should be a straightforward path. To what degree does Vertex have confidence in the overall contract manufacturing and the approval with that CMC company?
Sure. In any given six-month priority review, there is a set cadence of events, meetings with FDA, inspections, et cetera. We don't go into any of the specifics, but we have been confident in saying, and I'll repeat today, that everything has happened that should be happening.
We remain fully on track for November 30th. Without going into any of the specifics, things are looking good, and as I said, we're launch-ready and excited to go.
Fantastic. On one side, while you guys remain confident on that and everything remains on track, also the overall profile of the drug, including the fact about efficacy, safety, and convenience, I think are important aspects of pove versus your competitors. Meaning strong efficacy, arguably best in class.
Strong convenience, once-a-month pen.
Auto-injector, yep.
Versus others, which are IV or weekly injections. So you have the best in class. On the other side, some investors worry about the overall safety profile because of the potential risk of hypogammaglobulinemia and the reduction of IgG. Can you speak to Vertex's view about the safety profile of the drug, phase III was presented recently, and whether or not the label or monitoring should be or would be any different than the other approvals?
Great. You have our trifecta of differentiation. Thank you, Mike.
Yeah.
It is on efficacy where, recall it was just at 36 weeks, some of the peers were at 40, but we had greater than 50% reduction in proteinuria. We had greater than 80% resolution of hematuria. You had more than 40% of patients getting to KDIGO guidelines. I think that really does stack up very nicely versus the competitor potential best in class, although there are no head-to-head studies. I think looking very, very good there. On safety, I will get to your question in a second. As you mentioned, in terms of the patient features, it is the lowest dose, 0.46 ml. It is also lower viscosity than peers, so it is less painful. It is an auto-injector at home versus prefilled syringes, and it is monthly, as you said, versus one competitor's monthly, but a prefilled syringe, and the other is weekly.
In respect to expectations for the label and monitoring, I think the hypogammaglobulinemia, quote-unquote, "issue," if you will, has been more of a street issue.
Okay.
The so what of hypo IgG is infection rates. That is where you saw in our study very, very low rates from serious infection, and it was the exact same, 0.5%, in both the placebo-controlled arm as well as in the pove arm. We would not expect to see anything differentiated in terms of monitoring required and would expect a label consistent with peers.
Yeah. Just because there was frequent and regular monitoring during the phase III clinical trial, which you would expect in a clinical trial, we're observing safety, monitoring patients, they're coming in and having regular visits, as were the other drugs as well. That's to see if there are any safety issues as you're monitoring them.
Correct.
Vertex has remained confident that there were none, and that therefore there shouldn't be any abnormal monitoring because—
Exactly.
—that is your view.
That's right. That's our view.
I believe that other drugs, including FcRns, also have very deep IgG reductions and also not have any monitoring issues as well.
That's right.
This would be like a theoretical concern. But has this issue been raised or has it been discussed, and you sense that there's no concern or otherwise differentiation because of that profile versus others?
That's right. I think just to be aware is that there were different frequency of monitoring—
Okay
—among the peers. It's always perilous, I think, to compare across trials, particularly when it comes to this type of thing. We did check monthly.
Yeah.
A single excursion would be counted as event, where I believe peers were every 12 weeks, and you needed two sequential. I think just apples and oranges. Again, we don't believe, I think infection rate is the ultimate so what, and there we have the data, and there it's low and equivalent in both arms.
Okay. If we get an on-time approval by the end of the month, could happen any day theoretically, and the label doesn't require monthly or some regular monitoring, then you would have the potential best-in-class profile.
That said, there are two other drugs that were also approved in the last 12 months, Otsuka and Vera, and they've been off to a great launch. On one hand, it's a great launch, big market. On the other hand, you're launching third to market. Many people think that those companies have already sucked up a lot of the early bolus. They're already ahead of you. They've been out marketing. How does Vertex feel about being very competitive in the first 12 or 24 months? Investors are going to be very hyper-focused on managing all of this and comparing, and very specifically for investors, the numbers like 350 new patients per quarter are something that some of the other companies are putting out. Do you think that you can be as strong as those launches?
How does Vertex feel about those launches, even just starting with the fact that the—
Sure
—fourth quarter, we're going into the holidays, and then first quarter is always seasonally a challenge because new healthcare insurance plans. Maybe just talk to that and preview, if this is getting approved, should investors expect a super strong launch?
I think that, to your point, it has been exciting to see the launches from competitors and speaks to the fact that there are 160,000 biopsy-confirmed diagnosed patients with IgAN in the U.S. They are typically younger, otherwise healthy. They've been waiting for solutions. They've been ticking time bombs. They've been waiting for disease-modifying solutions here. I think that said, though, this can largely be sort of a discussion of TAM versus share. We certainly expect and hope and plan to gain more than our fair share, but I do think that we're very excited about the overall patient population market potential.
With the better-than-expected, I think, versus street expectations for the launches for the other two competitors, I think we're very excited to see that, and that underlines our confidence in this space. But even with saying 5,000 patient starts, right, that still leaves 155,000 patients for us to go after. I think we are very excited for the opportunity. Our sales force is trained. Over 90% of them have prior nephrology experience because not only are they excited about the differentiated profile of pove and IgAN, but they see the pipeline behind that of disease-modifying therapies in renal—
Right
—this whole renal renaissance. We will have the largest share of voice in terms of that field force and are really excited to go get it.
Right. Your point was that you have hired a sales force already, they are experienced, and that one of the advantages that Vertex may have, actually, this will lead us into the second drug, is that you have a franchise of other drugs that you will be selling to the same calling point at the nephrologist.
That is right.
It is not just like, "Oh, I work at Vera. I have got one product to sell." You would have multiple products—
That is right.
—in a portfolio, which will speak to the investment and the strength that you are putting into nephrology.
That is right. I will also add just quickly two other things. One is that we have had ongoing payer discussions.
Okay.
That will be an important part of this. We will also be offering what we feel will be a best-in-class patient support programs that we have learned and honed our expertise in the cystic fibrosis space. So when you are a patient, there is someone you can call. It is not a bot, a chatbot. It is an actual person who can help you navigate reimbursement, renewals, et cetera. Patients and physicians gain a lot of confidence from that.
I always like to pitch UBS Research, but we just had an expert call, and the doctor out of Boston, although it was local, said, "We've seen the Vertex salesperson already a bunch of times, more than the others." Vertex apparently is already out there marketing education, not the drug.
That's right.
A tidbit of that. You can check out the research if you want to.
I think there is good awareness.
This is what the doctor said.
It's been unbranded, right? We're really excited to be able to have on-brand FSGS.
Anyways, the point was that the awareness of the drug already is out there, and Vertex has been out there. If that is the case and that is underway, no shortness of other news coming out is that you said right around the corner in Q1 is the potential interim analysis for the phase III for inaxaplin, the second kidney drug.
For APOL1-mediated kidney disease, or AMKD. UBS Research thinks it could come very early in Q1, maybe around that other healthcare conference in San Francisco. Maybe you could just preview for us and set the table what Vertex thinks about the interim, what your base case assumption is for these results.
But there is an interim analysis also on eGFR, which is the more clinically accepted regulatory endpoint, not a surrogate like proteinuria. What does Vertex think will happen in these results, and what do you guys expect?
Yeah. So we are excited for it. To be clear, the regulatory endpoint is eGFR slope. I know there's been a lot of excitement and good work that PARASOL has done, but they're not there yet. The agency's not there yet in AMKD like they are for IgAN. But we've been very encouraged, if you recall, going way back, that published in the New England Journal of Medicine were the initial results with a 47.6% reduction—
Right
—in proteinuria at just 13 weeks. Then we had the AMPLIFIED results, which was in There were two cohorts. One cohort had more modest proteinuria, from 0.3 g to 0.7 g, and the other had type 2 diabetes. In the more modest proteinuria cohort, if you convert UACR to UPCR, again, it was in that mid to high 40% range, so—
This is important because the more modest group is a significant proportion of the phase III study, AMPLITUDE.
AMPLITUDE is actually more severe proteinuria.
The majority is severe. I am just saying there is a meaningful portion of it is also—
Of the patient population broadly, but AMPLITUDE is looking at the most severe patients. It is not FSGS, though. You can or you cannot have FSGS. We view the most important determinant is if you have the two APOL1 alleles—
Correct
—not whether you have had the histological diagnosis of FSGS. But we think the consistency of those results, even in the more modest proteinuria cohort in AMPLIFIED, as well as the earlier phase II study of more severe proteinuric patients, speaks to the mechanism of action here—
Right
—inhibiting APOL1. These patients, we know, progress more quickly in terms of their loss of kidney function over the course of a year. We are excited to show the difference versus placebo on top of standard of care at slope at 48 weeks. That will be the IA that hopefully positions us well for accelerated approval.
This population, for those that are still thinking about this result, this is a population where Vertex does think that the placebo arm or the untreated arm should have a very fast progression on eGFR. I think the company has said in the literature and the data support that the rate of eGFR progression is actually faster than those that are studied in IgAN.
Correct.
We have pretty good data on multiple studies now. If you model that out, then you have to make an assumption for the drug arm, less evidence around that, this is some of the work we did, but that you think that a 47%+ reduction in proteinuria should lead to a clinically meaningful slowing of that eGFR, and that is why you think it will be positive.
At 48 weeks, exactly.
We will see what those results. If that is the case, if you do hit that, UBS thinks there's a pretty good possibility of that happening. But if that does happen, then that means you would seek to file on accelerated approval?
Correct.
Okay.
There's no competition in this space, and probably a similarly sized patient population—
Right
—initially, largely in the U.S., about 150,000 patients. Then if you add in comorbidities like type 2, that's how you can get to about 250,000 patients.
Right.
Now, I will say these patients are not diagnosed, most of them, and will need the genetic test when we've been doing a lot of work in that area—
Right
—and would likely anticipate launching with a companion diagnostic. The first precision genetic medicine designed for this patient population.
Right. Speak to that a little bit. Again, I would just say it's interesting because it feels like Wall Street is like 80% vastly majority focused on IgAN.
Yeah, there's been approvals. Yeah, you're up for an approval date, so I can appreciate the focus. But if this AMKD study is positive, the patient population size to go after, that would be addressable by the results, which is all APOL1-mediated kidney disease, not just FSGS—
Right
—is similarly sized to IgAN, but yet there's no other competitors—
That is right
—in the space.
Exactly.
At least late stage. There would be two blockbuster franchises.
Okay.
I think that was a title of one of your recent books.
I think it was a title. Now, also to be balanced, you do need to go out and test for this. It is a genetic test.
The nephrologist would need to test for these patients and go find and build that.
Right.
But you guys have been working on that.
We have.
I've actually seen billboards and posters, at bus stops and other areas.
A lot of community—
Yeah
—and church group outreach. Alonzo Mourning's been tireless. He had the disease, an NBA Hall of Famer.
Right.
We're excited.
Okay. Then, so that is for Q1, so we'll look forward to that data. Now, also in the first half, you said, if I heard you right, because I have not been focused on this, is that the phase III data for diabetic peripheral neuropathy is also coming. So this is two phase III studies. Now, I feel like the data previously have been mixed, positive, mixed, hard to interpret. Can you speak to Vertex's confidence that, if I may just say JOURNAVX, although that's the branded name for the acute, is going to work in two phase III chronic pain indications? Because I feel like it is a high bar, but maybe you could speak to that.
Sure.
Maybe I'm wrong.
Yeah. The two phase III studies are on track to complete enrollment by the end of this year. They're both 12-week studies, and that's why we're seeing data by the middle of the year. If you recall, in the phase II study, we did see a two-point reduction in the NPRS score. In DPN, there is very high familiarity both in terms of clinical trial sites as well as manufacturers in terms of running these types of studies and managing the placebo effect, which is a significant element of ultimate trial success. Of the two studies, both are versus placebo, and then one of the studies also has a pregabalin arm as a comparator.
Okay.
We have had tremendous success with JOURNAVX on the acute side in terms of patient experience, increasing amounts of real-world evidence. We know that it is inhibiting the NaV1.8 channel. It will really just come down to managing placebo effect.
One study is placebo control. They are both placebo control.
Correct.
One of them has a third arm that is using pregabalin as an—
That is right.
—active control, just to see the relative—
As a comparator, right.
—reduction as a comparative. Obviously not powered to and compared to that.
Correct
The caveat to that is that the phase II results were basically testing in chronic pain, JOURNAVX versus LYRICA, and both of them were. There was no placebo arm, but they were blinded in what they saw, and the reduction in pain was similar in both arms.
Right.
It was promising, in your opinion.
That is right.
Okay. All right. Those phase III results will come. Now, I guess to speak to that, if the results are not what the company thinks, the strategy is combinations.
Is a combination drug, specifically a NaV1.7, in the clinic? If I am not mistaken.
It is not yet in the clinic.
Not yet.
Now, your sodium ion channels, you have nine of them. NaV1.7 triggers the pain sensation—
Yes
—and NaV1.8 propagates it.
Yes.
They're very hard to specifically inhibit, and that's why NaV1.8 came first.
Yes.
But we do think being able to do both, the trigger as well as the propagation, would have a synergistic effect in terms of efficacy. We have said we're in late preclinical for some time now.
Okay.
But I would say stay tuned to see us getting in the clinic, hopefully in 2027. And we would likely go straight to combination therapy, given that synergy that we're anticipating.
Okay. And how about just an update then on the acute pain program as well? Again, I feel like, to be fair, that Vertex has been historically very confident about this launch, blockbuster opportunity, true. Scripts are going up every day. We see them, yet the revenues were a bit flattish quarter-over-quarter. So can you just speak to my accuracy on those numbers? But the general fact that the scripts are going up nicely, but the revenues are not on pace to do hundreds of millions of dollars per year.
Yeah. We are on track for 2026 to more than triple prescriptions versus 2025. As you said, I think the Street has been really happy with the progression there. What we like to see too is the breadth of prescribers, from ER docs to OBGYNs, plastics, dentists, et cetera. Really good breadth of prescribers as well as depth of prescribers and settings of care. Recall this is a very broad label. Building a foundation for the long-term uptake of JOURNAVX. I will say, though, that Street has been a little disappointed on the revenue side of things with the revenue conversion rate. We were a little better than flat sequentially in Q3. It really has been, I think, running into the reality of reimbursement.
The pace at which we've been able to convert plans, get those plans and their child plans to come on board, some of the logistics of writing a script for 29 tablets for 14 days, not 28, not 30, et cetera. Then we had two big Medicare Part D plans come on board July 1st.
Okay.
Some drug that had been running through at a full price then was at the contracted price.
Now you have two big plans that are on.
Correct. Yes.
Okay.
Yeah. I think on track. The story in pain is acute pain, we continue to make progress. We'll leave the patient support program, that free drug, on until the middle of next year and gradually start phasing it out. You'll see better revenue conversion, gross to net normalizing by the middle of next year in the mid-50% range. Then you'll have the chronic pain results, and then you have the combo use.
Okay.
That's sort of the story in pain.
All right. If there wasn't enough for nephrology, two potential drugs, there's actually more, but we'll save that. PC1, I think is another, is a third drug in the clinic. We'll save that for another time. Two, if not three potential nephrology drugs. And then the pain franchise, which will have phase III data shortly. You also, if you weren't busy enough, did a $10 billion acquisition of Crinetics. My question is, what is Vertex's confidence in that opportunity in CAH? Because the data in phase II were positive, but you are running a phase III.
I do not recall that Vertex has been specific about the timing of the phase III and the results. Actually, since UBS covered Crinetics, it felt like phase III data may be 2028. Is that the right timeline, and what should we speak to that? Is there any update on any data on Crinetics and CAH?
Sure. The phase III study in adults with CAH is ongoing.
Okay.
We expect to complete enrollment in Q1 of 2027.
Okay.
There will be 32 weeks of dosing. In terms of data disclosure, think of it as a late 2027 or early 2028 event.
Hmm. Okay. All right. We'll write the major phase III results end of 2027, early 2028. Thank you for that. There's also an ongoing additional phase II study in pediatrics.
Yep.
Right. When Crinetics was approved, there was positive data in adults, but pediatrics, is there going to be data disclosure on that study?
We haven't put a timeline on that one yet. I should add for the phase III, in general, our goal with atumelnant is to show that we can normalize androgen levels, A4 specifically, while allowing patients to decrease their glucocorticoids down to physiologic levels.
Right.
We saw that in the phase II, and that's what we're aiming to show in the phase III. atumelnant is the only drug that is trying to go for this profile.
Right.
On the subject of the phase II in adults, I will mention there's the ongoing open-label extension study.
Okay.
We expect to share data from that at a medical meeting next year.
The reason I ask about the phase II ongoing is just because Wall Street, while focused on efficacy, has also been focused on liver safety—
Yeah
—and ALT elevations. So, clean results in the phase II in pediatrics would give us comfort on that.
Sure.
Meanwhile, the phase III is enrolling, so no news is good news, actually, on that front. But look forward to the phase II in pediatrics as well.
I would like to add to that, on the open-label extension, the phase II in adults, we have not seen any liver issues—
Okay
in the ongoing.
Okay. Good to know. All right. Fantastic. So plenty of things going on. We don't have enough time to finish all of it. We look forward to potential news later this month, as well as obviously updates in Q1. A lot going on and a fantastic 2027. So thank you guys very much.
Great. Thanks, Mike. Appreciate it.